Drugs Consultative Committee Turns Down Proposal to Make Medicine Batch Test Reports Publicly Accessible

The Drugs Consultative Committee has rejected a plan to mandate pharmaceutical firms to post batch test results and Certificates of Analysis on a public digital portal, according to minutes from its 18 September meeting.

Questions regarding the safety, purity, and clinical integrity of commercially available medicines frequently trouble patients and healthcare professionals alike. A widespread concern among consumers is whether the general public should have transparent access to laboratory evaluation records for the specific batches of medicines they purchase over retail pharmacy counters. Addressing these very questions, an ambitious reform had surfaced before India's apex pharmaceutical regulatory advisory council to establish an open digital repository where manufacturing units would be legally mandated to publish their routine batch inspection findings. That proposal, however, has been formally turned down by the regulatory body.

Verdict Documented in DCC 70th Meeting Minutes
The regulatory deliberation took place during the 70th assembly of the Drugs Consultative Committee (DCC) held on 18 September. The official meeting minutes reveal that the committee explicitly declined the proposition requiring pharmaceutical makers to open up their quality testing certificates to the general public. Functioning as a high-level statutory advisory entity, the DCC brings together central and state-level drug controllers on a single forum. Its primary responsibility lies in orchestrating regulatory uniformity, facilitating operational coordination, and guiding policy implementations across state boundaries and central authorities.

The Proposed Public Digital Repository
Under the draft recommendation brought before the committee, an online public platform was intended to serve as a comprehensive transparency mechanism for pharmaceutical quality control. Pharmaceutical manufacturers would have faced a mandatory compliance obligation to upload either the detailed test reports or the formal Certificate of Analysis (CoA) for every single commercial batch rolled out of their production lines. Had this measure received regulatory clearance, any healthcare practitioner, patient, or researcher would have possessed the technical ability to view real-world batch verification metrics online before prescribing or consuming a therapeutic product.

Understanding the Certificate of Analysis
Whenever a pharmaceutical company finishes manufacturing a designated batch of pharmaceutical formulations, the entire lot undergoes extensive chemical, physical, and microbiological evaluations to verify compliance with pharmacopoeial criteria. Upon conclusion of these evaluations, the company issues a structured technical record officially designated as the Certificate of Analysis. This document verifies that the specific production lot was systematically inspected against defined quality benchmarks and articulates the precise numerical or qualitative outcomes observed during laboratory screening.

Debating Consumer Transparency Against Regulatory Oversight
The fundamental impetus behind recommending open access was to dismantle informational opacity around pharmaceutical production. Theoretically, allowing open scrutiny of batch testing records empowers physicians, pharmacists, and end consumers to verify whether individual lots conformed to acceptable standards during factory-level clearance. Nevertheless, the committee had to evaluate considerations reaching beyond broad notions of public transparency. The members weighed how drug quality surveillance is structurally executed and what formal regulatory mechanisms should govern the assessment process. Following these deliberations, the DCC decided against obligating manufacturers to post Certificates of Analysis on an open portal.

What this means for you
This decision means ordinary patients and healthcare consumers will not be able to directly inspect batch-level laboratory clearance reports for medicines sold in the market.

• Impact on Consumers: You cannot independently inspect the official laboratory test documents for the specific medicine batch you purchase from a chemist. Verification of pharmaceutical efficacy will remain entirely under the purview of existing statutory drug regulators rather than open public review.
• Status of Transparency: Pharmaceutical companies will face no mandatory requirement to upload Certificates of Analysis onto an open digital website. As a result, end buyers are unable to cross-reference product batch numbers against digital laboratory findings.
• Implications for Doctors: Healthcare providers prescribing treatments will also lack an open repository to independently inspect manufacturer batch metrics. Medical practitioners must continue to rely solely on existing standard regulatory clearances.
• Regulatory Surveillance: Drug quality enforcement remains strictly confined to administrative channels overseen by state and central inspectors. Any formal quality grievance will follow routine bureaucratic complaint procedures rather than transparent public audit portals.

Why this happened
The proposal to mandate the public disclosure of batch testing records was declined following a comprehensive regulatory review by the Drugs Consultative Committee.

• Origins of the Proposal: The recommendation was initiated to enhance transparency across the pharmaceutical supply chain by giving consumers and health professionals direct access to testing records. It aimed to obligate all manufacturers to post Certificates of Analysis on a public digital portal.
• Regulatory Assessment: During its 70th meeting, the committee scrutinized the practical operational framework of drug surveillance. The body evaluated whether public reporting aligned with the statutory supervisory structure currently governing the pharmaceutical sector.
• Final Administrative Action: Following consultations between central and state drug authorities, the council concluded that mandating public online uploads was not advisable within the existing framework. Consequently, the resolution to dismiss the recommendation was formally documented in the 18 September meeting minutes.

Questions & Answers

1. What decision was made by the Drugs Consultative Committee?
The DCC rejected a proposal that sought to mandate pharmaceutical manufacturers to upload medicine batch test reports and Certificates of Analysis to a public digital platform.

2. When was this regulatory decision formally taken?
The decision was recorded in the minutes of the DCC's 70th meeting, which took place on 18 September.

3. What is a Certificate of Analysis in pharmaceuticals?
It is an official quality document issued after testing a manufactured medicine batch, verifying that the batch met required quality standards along with its test results.

4. What did the rejected proposal originally require?
It recommended creating a centralized public online platform where manufacturers would be obligated to post test reports for every batch for public viewing.

5. What is the function of the Drugs Consultative Committee?
The DCC serves as an advisory body comprising central and state drug regulators to ensure coordination and consultation on pharmaceutical regulatory policies across India.

https://trendkia.com/en/health/davaon-ke-baicha-testa-ki-riporta-pablika-karane-ka-prastava-kharija-drugs-consultative-committee-ne-liya-phaisala-41999
TrendKia — Har trend, sabse pehle.